Actinium Pharmaceuticals Inc (ATNM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Actinium Pharmaceuticals Inc (ATNM) has a cash flow conversion efficiency ratio of -2.548x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.87 Million) by net assets ($2.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ATNM net asset quality score to measure how much of total assets are equity-financed.
Actinium Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Actinium Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ATNM cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Actinium Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Actinium Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Birko Birlesik Koyunlulular Mensucat Ticaret ve Sanayi AS
IS:BRKO
|
0.031x |
|
CID HoldCo, Inc. Common Stock
NASDAQ:DAIC
|
0.323x |
|
Brand 24 SA
WAR:B24
|
0.338x |
|
Senetas Corporation Ltd
AU:SEN
|
-0.024x |
|
LOOP INDUSTRIES DL-001
F:3L9
|
0.241x |
|
Jericho Oil Corp
V:JEV
|
-0.137x |
|
Hancom WITH Inc
KQ:054920
|
-0.060x |
|
Home Capital Rentals SOCIMI S.A.
MC:YHCR
|
0.021x |
Annual Cash Flow Conversion Efficiency for Actinium Pharmaceuticals Inc (2006–2025)
The table below shows the annual cash flow conversion efficiency of Actinium Pharmaceuticals Inc from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see Actinium Pharmaceuticals Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $7.83 Million | $-24.58 Million | -3.138x | -210.78% |
| 2024-12-31 | $32.76 Million | $-33.07 Million | -1.010x | +22.41% |
| 2023-12-31 | $36.38 Million | $-47.34 Million | -1.301x | -1100.72% |
| 2022-12-31 | $66.48 Million | $8.64 Million | 0.130x | +145.83% |
| 2021-12-31 | $73.55 Million | $-20.87 Million | -0.284x | +19.52% |
| 2020-12-31 | $61.32 Million | $-21.62 Million | -0.353x | +90.73% |
| 2019-12-31 | $5.64 Million | $-21.46 Million | -3.802x | -62.89% |
| 2018-12-31 | $8.81 Million | $-20.57 Million | -2.334x | -48.06% |
| 2017-12-31 | $13.67 Million | $-21.55 Million | -1.577x | -36.57% |
| 2016-12-31 | $18.01 Million | $-20.79 Million | -1.154x | -36.80% |
| 2015-12-31 | $21.97 Million | $-18.54 Million | -0.844x | -111.31% |
| 2014-12-31 | $-1.92 Million | $-14.35 Million | 7.463x | +84.98% |
| 2013-12-31 | $-1.56 Million | $-6.29 Million | 4.035x | +188.68% |
| 2012-12-31 | $1.15 Million | $-5.21 Million | -4.550x | -71087.78% |
| 2011-12-31 | $-84.33K | $539.00 | -0.006x | +92.28% |
| 2010-12-31 | $-94.62K | $7.83K | -0.083x | -142.45% |
| 2009-12-31 | $-96.29K | $-18.78K | 0.195x | +3.32% |
| 2008-12-31 | $-73.96K | $-13.96K | 0.189x | -59.53% |
| 2007-12-31 | $-33.20K | $-15.49K | 0.467x | -38.81% |
| 2006-12-31 | $-18.40K | $-14.03K | 0.763x | -- |
About Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular… Read more